Kettering Health first to offer breast cancer ‘radiotracer' option
Kettering Health is the first and only health system in southwest Ohio to participate in a post marketing clinical trial evaluating GE Healthcare's...
Kettering Health is the first and only health system in southwest Ohio to participate in a post marketing clinical trial evaluating GE Healthcare's diagnostic radiotracer, CeriannaTM (fluoroestradiol F18) injection, clinical utility to guide therapeutic management in metastatic breast cancer patients.Cerianna, FDA approved since May 2020, is a radioactive diagnostic agent that binds to estrogen receptor positive (ER+) lesions in patients with recurrent or metastatic breast cancer. Cerianna is used with PET imaging as an adjunct to biopsy.